You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
McKinsey
Harvard Business School
Baxter

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for PF-04958242


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug PF-04958242?

PF-04958242 is an investigational drug.

There have been 14 clinical trials for PF-04958242. The most recent clinical trial was a Phase 1 trial, which was initiated on November 15th 2018.

The most common disease conditions in clinical trials are Schizophrenia, Cognition Disorders, and Deafness. The leading clinical trial sponsors are Pfizer, Biogen, and Yale University.

There are thirty-eight US patents protecting this investigational drug and three hundred and fifty-one international patents.

Recent Clinical Trials for PF-04958242
TitleSponsorPhase
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese ParticipantsBiogenPhase 1
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)BiogenPhase 2
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)PfizerPhase 2

See all PF-04958242 clinical trials

Clinical Trial Summary for PF-04958242

Top disease conditions for PF-04958242
Top clinical trial sponsors for PF-04958242

See all PF-04958242 clinical trials

US Patents for PF-04958242

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-04958242   Start Trial 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides Pfizer Inc. (New York, NY)   Start Trial
PF-04958242   Start Trial Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors Pfizer Inc. (New York, NY)   Start Trial
PF-04958242   Start Trial Imidazopyridazine compounds Pfizer Inc. (New York, NY)   Start Trial
PF-04958242   Start Trial N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiaz- in-8a(8H)-YL)-1,3-thiazol-4-YL] amides Pfizer Inc. (New York, NY)   Start Trial
PF-04958242   Start Trial Pyrazolopyrimidine compounds Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-04958242

Drugname Country Document Number Estimated Expiration Related US Patent
PF-04958242 Argentina 099997 2034-04-10   Start Trial
PF-04958242 Australia 2015245260 2034-04-10   Start Trial
PF-04958242 Canada 2944971 2034-04-10   Start Trial
PF-04958242 Chile 2016002510 2034-04-10   Start Trial
PF-04958242 China 106459088 2034-04-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
McKesson
Moodys
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.